If you are an athlete or a bodybuilder looking for ways to decrease body fat whilst increasing muscle mass then GHRP 2 and GHRP 6 (the two types of Growth Hormone Releasing Peptides) can certainly help you with your requirements. The best part with these hormones is that you are likely to get the desired results out of them, especially when you combine them with muscle building and fat-burning foods, aerobic and intense strengthening exercises. However, there are subtle differences between the two hormones that you cannot ignore. 
The response of these wounds reminds us of the pattern of healing described for MG53 protein (a membrane repair machinery member), so that the treatment facilitated wound healing along with a reduced scarring in rodent models. This antiscar effect was explained by interfering with TGF-β-dependent activation of myofibroblasts differentiation and reduction of ECM proteins accumulation [22]. Similarly, antiscarring healing properties are described for plants’ principles that downregulate the expression of fibrogenic-related molecules such as TGF-β1 and the downstream events, leading to fibrosis and scar formation [23]. In addition to a direct action of GHRP-6 on TGFB1 gene expression, we deem that the reduction of inflammatory effectors could have also contributed to enhancing the healing process and to reducing fibrosis. In an animal model of liver ischemia/reperfusion, we previously demonstrated that GHRP-6 prevented internal organs parenchymal activation and the onset of a systemic inflammatory response syndrome by downregulating proinflammatory cytokines [24]. Subsequent studies have demonstrated the ability of different GHRPs to ameliorate local and systemic inflammatory processes in a variety of experimental scenarios by suppressing the activation of NF-κB, the consequent expression of proinflammatory cytokines, and acting as chemokine receptor antagonist [25–27]. Differentiation to myofibroblasts, collagen fibrillogenesis, and matrix accumulation are controlled by opposing forces: proinflammatory and profibrogenic, that require a fine tuning to ensure a proper esthetic healing and effective mechanical properties of the ECM [28, 29]. The overall interpretation of the data from (i) the rate of closure, (ii) microscopic appearance of the collagen fibrils alignment/organization, (iii) impact of the treatment on the transcriptional expression of cytoskeleton filamentous proteins (smooth muscle α-actin (α-SMA), desmin, and vimentin) supports the hypothesis that, in this context, GHRP-6 has shifted the balance toward “a more regenerative” rather than a reparative phenotype.
Biokey Research OSTA-MAX 25 BRAND: BIOKEY RESEARCH  OSTARINE (MK-2866) Purity : 99% Molecular Formula : C19H14F3N3O3 Molecular Weight: 389.33 CAS#: 841205-47-8 Description: MK-2866 Ostarine 30ml @ 25mg per ml Recommended dosage: 0.5-1ml daily DESCRIPTION OSTA-MAX 25 by BioKey Research contains 25mg/ml of MK-2866. This compound is often compared it its illegal anabolic counterparts due its ability to reduce body fat while increasing lean muscle mass. OSTA-MAX 25…

As the name indicates, this peptide is a fragment of human growth hormone. It is more specifically a modified form of the amino acids 176-191 in the C-terminal section of the latter substance. Bodybuilders mainly use it enhance fat burning for improved and more noticeable muscle growth. For weight loss, HGH Fragment 176-191 is thought to be considerably more potent than regular growth hormone. It also offers anti-aging benefits as a result of positive effects on IGF-1 levels.

Growth Hormone Releasing Peptide 6 ( GHRP-6) is a peptide which substantially activates the pituitary gland into releasing high levels of growth hormone for a few hours. The increase in growth hormone comes from your own body, not synthetic growth hormones which can suppress your natural production. GHRP 6 is a first generation GHRP and has a few side effects which could be annoying.

Ghrelin has many activities in the body besides stimulating GH release. It stimulates appetite, is cardioprotective, can help protect cells against oxidative damage, can reduce inflammation and promote healing, and can promote fat-burning in muscle. There is also some effect on increase in cortisol production via increase in ACTH, and increase in prolactin. However, where the activity of ghrelin is comparable to that which ordinarily occurs during fasting, effects on cortisol and prolactin likewise are comparably only to that experienced while fasting.

Additionally and not less relevant, GHRP-6 appears as an excellent partner to combine with other molecules (ie, epidermal growth factor [EGF]) because their exclusive actions seem to achieve a kind of synergism, useful to target the multiples nodes of complex pathophysiological processes, and thus to enhance tissue repair processes.56 Garcia del Barco and coworkers in our group have opened unprecedented avenues, by combining GHRP-6 and EGF as a therapeutic approach to ameliorate the damages of multiple sclerosis,57 peripheral axonal pathology,58 and brain ischemia in animal models.59,60 They have demonstrated that in all these experimental substrates the combined action of GHRP-6 and EGF is associated with a better outcome in both clinical and pathological fields.
CJC-1295 is basically a peptide hormone that acts similar to growth hormone releasing hormones (GHRH). Invented by a Canadian biotechnology company called ConjuChem, it is beneficial to athletes because it can bioconjugate with circulating albumin and increase the time it can be used for medical purposes. It achieves this by preventing degradation of its amino acids. With a single dose, it can remain in the body for quite a few days and can cause the growth hormone to be released many times per day. This reduces the frequency of injections needed.
In addition to its cytoprotective effects, growth hormone-releasing peptide 6 (GHRP-6) proved to reduce liver fibrotic induration. CD36 as one of the GHRP-6 receptors appears abundantly represented in cutaneous wounds granulation tissue. The healing response in a scenario of CD36 agonistic stimulation had not been previously investigated. Excisional full-thickness wounds (6 mmØ) were created in the dorsum of Wistar rats and topically treated twice a day for 5 days. The universal model of rabbit’s ears hypertrophic scars was implemented and the animals were treated daily for 30 days. Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL. Wounds response characterization included closure dynamic, RT-PCR transcriptional profile, histology, and histomorphometric procedures. The rats experiment indicated that GHRP-6 pharmacodynamics involves attenuation of immunoinflammatory mediators, their effector cells, and the reduction of the expression of fibrotic cytokines. Importantly, in the hypertrophic scars rabbit’s model, GHRP-6 intervention dramatically reduced the onset of exuberant scars by activating PPARγ and reducing the expression of fibrogenic cytokines. GHRP-6 showed no effect on the reversion of consolidated lesions. This evidence supports the notion that CD36 is an active and pharmacologically approachable receptor to attenuate wound inflammation and accelerate its closure so as to improve wound esthetic.
Author Contributions: Conceived and designed the experiments: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB, GGN. Analyzed the data: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB. Wrote the first draft of the manuscript: JBA. Contributed to the writing of the manuscript: JBA, AGO, YMM. Agree with manuscript results and conclusions: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB, QB, GGN. Jointly developed the structure and arguments for the paper: JBA, AGO, GGN. Made critical revisions and approved final version: QB, GGN. All authors reviewed and approved of the final manuscript.
For example, there are Growth Hormone Releasing Peptides (GHRP’s with names such as ipamorelin and hexarein) which allow for a slow and steady growth hormone release that produces a pulse which mimics natural growth hormone release times and Growth Hormone Releasing Hormones (GHRH’s such as Mod-GRF) for an even stronger natural release of growth hormone and greater presence of growth hormone precursors known as GH “frags” or fragments.
Serum ghrelin levels vary as a function of energy balance. Ghrelin levels are increased in anorexia and decreased in obesity.78 Thus, it is possible that ghrelin may be an important player in food intake behavior and perhaps in chronic over- and under-nutrition as well.9 Because of its dual effects, ghrelin may be a critical hormonal signal of nutritional status to the somatotropic axis, playing a role in integrating energy balance with the growth process.10
I have been using sermorelin (bioidentical growth hormone releasing hormone) for 2 months now to help heal a nasty right quad tendon rupture suffered the end of December. I’m 52 years old with 7% bodyfat and am a lifetime strength trainer and former high level bike racer. 2 months ago, in spite of months of religious rehab, I couldn’t do a single right leg bench stepup. Yesterday I was doing 20lb DB’s for repeated sets of 15. I get complete blood panels every 6 months, and my last labs in May showed my IGF-1 levels off the reference range low. I get my next bloods in a couple of weeks. I was initially afraid to try this hormone due to the cancer implications, and I didn’t need it to be lean and fit, but I was desperate and for my injury recovery, and it has made a significant difference. Plus, I believed supplementing the releasing hormone vs, IGF-1 limits the possibility of increasing the levels too much, as well as causing a negative feedback loop. By the way, I also tried TB-500 previous to the sermorelin, and it seemed to make some other achy joints in the gym go away, but didn’t seem to help the quad injury.
The mechanisms supporting the GHRP-6-mediated HTS prevention may be related to a potential modulation of the fibrogenic response, especially by TGF-β1 transcriptional deactivation and its downstream effector CTGF, as has been previously described [30]. Nevertheless, we have not elucidated the pathways involved in the GHRP-6-mediated TGFB1 gene expression reduction. Under these circumstances, we have reproducibly observed [7] that GHRP-6 increases PPARG expression which may have counteracted TGF-β1-associated fibrogenic input. The fact that CD36 occupation by GHRP-6 upregulates PPARG gene expression is noteworthy in this context and represents an additional pharmacologic property for this peptide. Although the molecular pathways underlying the antifibrotic effects of PPARγ remain elusive, an antagonistic relationship is proposed between PPARγ and TGF-β1 signaling in fibrosis. For more than a decade ago, PPARγ has been reputed as a fibrosis-response regulating factor and its activation represents an innovative pathway to control fibrotic diseases [31, 32].
CJC-1295 is basically a peptide hormone that acts similar to growth hormone releasing hormones (GHRH). Invented by a Canadian biotechnology company called ConjuChem, it is beneficial to athletes because it can bioconjugate with circulating albumin and increase the time it can be used for medical purposes. It achieves this by preventing degradation of its amino acids. With a single dose, it can remain in the body for quite a few days and can cause the growth hormone to be released many times per day. This reduces the frequency of injections needed.
Adults do not stop producing growth hormone as they get older; in fact, it's a myth that's spread by the HRT/TRT industry. However, as you get older, it's harder to activate the body’s release or pulse of growth hormone as frequently as you did when you were still growing; hence, the term “when I was younger...”. Who doesn't remember how great they felt at 18, versus 38!
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used in the management of mild to moderate pain and inflammation in conditions such as dysmenorrhoea, headache including migraine, post-operative pain, dental pain, musculoskeletal and joint disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile idiopathic arthritis, peri-articular disorders such as bursitis and tenosynovitis, and soft tissue disorders such as sprains and strains. It is also used to reduce fever.
Manipulation of somatostatin tone also affects the GH response to GHSs. When hexarelin was given to subjects in combination with somatostatin, the amount of GH released was significantly reduced. When arginine, a postulated inhibitor of somatostatin, was administered to older adults, a group proposed to have increased somatostatin tone, GH levels following the administration of GHRP-6 increased significantly, to levels seen in younger subjects.
A peptide is an amino acid chain (amino acids being the building blocks of proteins), responsible for signalling different responses in the body. These amino chains already exist in the body in one form or another, which is why some consider them as ‘natural’ compounds (although testosterone exists in the human body too, adding extra is considered cheating in most cases). Peptides have been classified in research and manufacture according to a number sequence in many cases, which is why some are just numbers and letters (see later).
Paracetamol is distinct from non-steroidal anti-inflammatory drugs (NSAIDs). It is a para-acetylaminophenol with both analgesic and antipyretic properties. Originally synthesized in the 1880s and first released for use on prescription in 1955 in the USA and on 1956 in UK. It has been available in most countries, without prescription, for many years. Recent data suggests it acts via a central mechanism, whereby it is deacetylated to 4-aminophenyl and then conjugated with arachidonic acid to form N-arachidonoylphenylamine which is an exogenous cannabinoid (Hogestatt ED et al. 2005).
In a study designed to assess the effect of both the estrogen and GHRP-6 on the cardiovascular and metabolic diseases in ovariectomized (OVX) rats, Elbassuoni, et al found that although GHRP-6 failed to produce significant change in body weight gain and food intake, it clearly reversed the effect of OVX on fasting serum glucose, insulin, insulin resistance, and the assessed lipid fractions. They concluded that the effect of GHRP-6 on improving dyslipidemia after OVX was even more potent than that of estrogen.12 Furthermore, the mechanism of action of GHRP-6 has been more extensively studied in experimental models with obese subjects, and was shown to be a powerful GH releaser in obesity, and to release GH independently of the hypothalamic factors (GHRH and somatostatin).13
Various experiments have been conducted to test the effectiveness of CJC 1295-DAC in vivo and the Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection. Mean half-life was shown to be 5.8-8.1 days, also after multiple doses mean IGF-1 levels remained above baseline for up to 28 days. No serious adverse reactions were reported in any group.
Extreme hunger stimulation: It has been previously mentioned in this profile already that almost all GHRPs will stimulate hunger simply by virtue of the fact that they are Ghrelin mimetics (they mimic the action of the hormone Ghrelin in the body), but GHRP-6 has demonstrated both anecdotally as well as clinically to stimulate the largest hunger increases in comparison to all other GHRPs[2]. GHRP-6 tends to stimulate what can only be described as agonizing hunger, and is commonly misconceived as a hypoglycemic episode. The hunger resultant from GHRP-6 is, in fact, simply the peptide acting on Ghrelin receptors that signal hunger to various regions in the brain. No studies or any anecdotal evidence demonstrates hypoglycemic blood glucose readouts following GHRP-6 administration. Following a meal, the hunger should subside. Many users have also reported the intensity of the hunger diminishing several weeks into GHRP-6 cycles but not completely disappearing.

Essentially a synthetic version of ghrelin analogue, GHRP-6 (like GHRP-2) stimulates the release of an endogenous growth hormone (GH) within the somatotropes of the anterior pituitary in the animal and human body. Specifically, GHRP-6 will increase the number of somatotropes in a GH pulse by limiting the amount of somatostatin present, while standard GHRH increases the amplitude at which the pituitary cells pulse. Unlike ghrelin, GHRP-6 is not specifically used to increase appetite, but it may have secondary actions that impact hypothalamic neurons. These effects last for approximately an hour after the initial application, which mimics the natural application of GH, and consists of an eight hour circulation period.
When you increase the dosage gradually it is also going to ensure you do not experience all (or any) of the noted side effects which are possible with the use of Ipamorelin. And, if you are taking other peptides, supplements, or growth hormones, it is the best way to ensure they are going to acclimate well and work together well, in order for you to realize the greatest results possible when trying to increase muscle mass, and lean muscle tissue, without putting on body fat in the process.
GH’s big USP is its ability to overcome injuries thanks to its restorative properties. Sadly, this notion is still in the firmly in the journal of bro-science. Research in the Clinical Science found when pigs were injected daily with GHRP-6 it had powerful antioxidant effects that could reduce internal heart attack damage. Your DNA isn’t bacon, but it does offer the telltale signs of a potential healing agent and many lifters do report success with restoring long-term overuse injuries, such as tendinitis or rotator cuff niggles. So while beefed up singlet-wearers have sung its praise, the labcoat-wearers haven’t confirmed its scientific efficacy just yet. So watch this space for the new GHRP-6 science that could keep your physique in the sweat game.